Dividendos de Collegium Pharmaceutical

Dividendo controles de criterios 0/6

Collegium Pharmaceutical no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.4%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	US$1.47
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30

Sizing Up Collegium Pharmaceuticals

Oct 04

Collegium Pharmaceutical: Moving Closer To The Top

Jul 12

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment

May 14

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

May 13

We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

May 01

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de COLL han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de COLL han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Collegium Pharmaceutical vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de COLL con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (COLL)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.7%
Media de la industria (Pharmaceuticals)	2.4%
Previsión de analistas en 3 años (COLL)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de COLL en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de COLL en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de COLL para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que COLL no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de Collegium Pharmaceutical

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Collegium Pharmaceutical Q4: The Beat Goes On

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS exceeds analyst expectations

Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Executive VP & Chief Commercial Officer notifies of intention to sell stock

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Price target increased by 13% to US$37.75

President notifies of intention to sell stock

Executive VP exercised options and sold US$253k worth of stock

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

New minor risk - Shareholder dilution

Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 8.3% to US$33.25

Executive VP notifies of intention to sell stock

President notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & CFO notifies of intention to sell stock

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 12% to US$36.00

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target increased to US$34.00

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023

Co-Founder & Chairman notifies of intention to sell stock

Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents

Co-Founder & Chairman exercised options and sold US$1.3m worth of stock

President notifies of intention to sell stock

Insufficient new directors

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022

Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021)

Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Executive VP & CFO notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to US$31.40

Collegium Pharmaceutical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Collegium Pharmaceutical, Inc. Appoints Neil McFarlane to its Board of Directors

Consensus EPS estimates fall by 16%

Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Year 2022

Collegium Pharmaceutical, Inc. Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2022

Price target increased to US$27.71

Collegium Pharmaceutical: Thoughts After Another Strategic Move

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) entered into an agreement to acquire BioDelivery Sciences International, Inc. (NasdaqGS:BDSI) for approximately $580 million.

Investor sentiment improved over the past week

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) entered into an agreement to acquire BioDelivery Sciences International, Inc. (NasdaqGS:BDSI) for approximately $580 million.

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Price target increased to US$28.00

Collegium Pharmaceutical, Inc. Announces Settlement Framework to Resolve All 27 Pending Opioid-Related Litigation

Third quarter 2021 earnings released: EPS US$0.23 (vs US$0.33 in 3Q 2020)

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt